

Listing of the Claims

Following is a complete listing of the claims pending in the application:

1. (Currently amended) A method of decreasing IFN-γ blood levels preventing an increase in the blood level of IFN-γ in a subject at risk of with an elevated IFN-γ blood level due to (i) administration of a therapeutic agent for treating multiple sclerosis or (ii) a disease condition, comprising

orally administering an interferon-tau (IFNτ) having greater than about 80% homology to ovine interferon-tau to the subject at a dosage of greater than 5×10^8 between $6 \times 10^8 - 5 \times 10^{12}$ Units to decrease the subject's IFN-γ blood level relative to the IFN-γ blood level in the absence of IFNτ administration.

2. (Canceled)

3. (Currently amended) The method of claim [[2]] 1, wherein said IFNτ has a sequence identified as SEQ ID NO:2 or SEQ ID NO:3.

4. (Currently amended) The method of claim 1, wherein said orally administering is to a subject having an elevated IFN-γ level due to administration of the therapeutic agent interferon-beta an autoimmune condition, and said orally administering continues during the period of the subject's symptoms.

5-11. (Canceled)